{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:46:27Z","timestamp":1791315987159,"version":"4.3.1"},"reference-count":43,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2002,1,12]],"date-time":"2002-01-12T00:00:00Z","timestamp":1010793600000},"content-version":"vor","delay-in-days":286,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2001,4]]},"abstract":"<jats:p>The single most important prognostic determinant in childhood acute lymphoblastic leukaemia (ALL) is effective therapy and changes in therapy may influence the significance of other risk factors. The effect of intensified therapy on the importance of currently recognized phenotypic and genotypic determinants of outcome was assessed in 2090 children enrolled on the Medical Research Council United Kingdom acute lymphoblastic leukaemia XI (MRC UKALL XI) protocol. Treatment allocation was not determined by risk factors. Multivariate analysis confirmed the dominant influence on prognosis of age, sex and presenting white cell count (WCC). After allowing for these features, blast karyotype, d\u20038 marrow blast percentage and remission status at the end of induction therapy were the only remaining significant predictors of outcome. Organomegaly, haemoglobin concentration, French\u2013American\u2013British type, body mass index, presence of central nervous system disease at diagnosis, immunophenotype and presence of <jats:italic>TEL\/AML1<\/jats:italic> fusion gene (examined in a subset of 659 patients) either had no significant effect on outcome or were significant only in univariate analysis. Among karyotype abnormalities with an independent influence on prognosis, high hyperdiploidy (&gt;\u200350 chromosomes) was shown to be favourable, whereas near haploidy (23\u201329 chromosomes), presence of the Philadelphia chromosome, t(4;11) and abnormalities affecting the short arm of chromosome 9 [abn (9p)] were adverse risk factors. Early responders to therapy, determined by residual marrow infiltration after 8\u2003d of induction therapy, had a good outcome, while the small proportion of patients who did not achieve a complete remission by the end of induction therapy had a poor outcome. A third block of late intensification was shown to improve event\u2010free survival by 8% at 5\u2003years. The effect of these risk factors was not significantly different between those randomized to the third intensification block and those not randomized to a third block.<\/jats:p>","DOI":"10.1046\/j.1365-2141.2001.02668.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T06:33:10Z","timestamp":1047364390000},"page":"103-114","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":116,"title":["Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol"],"prefix":"10.1111","volume":"113","author":[{"given":"Ian","family":"Hann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Vora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osborn","family":"Eden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Richards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the UK Medical Research Council's Working Party on Childhood Leukaemia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2002,1,12]]},"reference":[{"key":"e_1_2_6_2_1","first-page":"502a","article-title":"Prospective assessment of the prognostic value of TEL\u2010AML1 expression in childhood acute lymphoblastic leukemia (ALL)","volume":"94","author":"Baruchel A.","year":"1999","journal-title":"Blood"},{"key":"e_1_2_6_3_1","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1182\/blood.V90.2.571","article-title":"Incidence and clinical relevance of TEL\u2010AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin\u2010Frankfurt\u2010Munster Study Group","volume":"90","author":"Borkhardt A.","year":"1997","journal-title":"Blood"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)90988-1"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1995.tb03313.x"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)90164-7"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.3493163.x"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400959"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(97)10295-1"},{"key":"e_1_2_6_10_1","first-page":"162","article-title":"Current results of studies of immunophenotype\u2010age and leukocyte\u2010based therapy for children with acute lymphoblastic leukemia. The Pediatric Oncology Group","volume":"6","author":"Crist W.","year":"1992","journal-title":"Leukemia"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00818.x"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400989"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.1997.tb08604.x"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.11.2234"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1097-0142(19971101)80:9<1717::aid-cncr4>3.0.co;2-b"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/080352598750031149"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401704"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401093"},{"key":"e_1_2_6_19_1","doi-asserted-by":"crossref","first-page":"4933","DOI":"10.1182\/blood.V90.12.4933","article-title":"Incidence of TEL\/AML1 fusion gene analysed consecutively in children with acute lymphoblastic leukemia in relapse","volume":"90","author":"Harbott J.","year":"1997","journal-title":"Blood"},{"key":"e_1_2_6_20_1","first-page":"1537","article-title":"Association of chromosome arm 9p abnormalities with adverse risk in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group","volume":"94","author":"Heerema N.A.","year":"1999","journal-title":"Blood"},{"key":"e_1_2_6_21_1","first-page":"483","article-title":"Impact of early intensive reinduction therapy on event\u2010free survival in children with low\u2010risk acute lymphoblastic leukemia","volume":"33","author":"Henze G.","year":"1990","journal-title":"Hamatological Bluttransfusion"},{"key":"e_1_2_6_22_1","first-page":"668a","article-title":"Should therapy be intensified for patients with good risk ALL?","volume":"88","author":"Hutchinson R.","year":"1996","journal-title":"Blood"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1992.tb08170.x"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.1002914.x"},{"key":"e_1_2_6_25_1","doi-asserted-by":"crossref","first-page":"4792","DOI":"10.1182\/blood.V92.12.4792","article-title":"Incidence of TEL\/AML1 infusion in children with relapsed acute lymphoblastic leukemia","volume":"92","author":"Loh M.L.","year":"1998","journal-title":"Blood"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.12.1807"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199806043382304"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1977.1"},{"key":"e_1_2_6_29_1","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/blood.V76.3.590.590","article-title":"Near\u2010Triploid and Near\u2010Tetraploid acute lymphoblastic leukaemia of childhood","volume":"76","author":"Pui C.H.","year":"1990","journal-title":"Blood"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.3.818"},{"key":"e_1_2_6_31_1","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1182\/blood.V79.12.3245.3245","article-title":"Hyperdiploid (47\u201350) acute lymphoblastic leukaemia in children","volume":"79","author":"Raimondi S.C.","year":"1992","journal-title":"Blood"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1026781"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.3.1150"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199605093341906"},{"key":"e_1_2_6_35_1","unstructured":"SAS Institute Inc.(1990)SAS Procedures Guide Version 6 (3rd edn). SAS Institute Inc. Cary NC."},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.5.1716"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.1.18"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.2.389"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.3.527"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1097-0142(19981101)83:9<2030::aid-cncr21>3.3.co;2-h"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.2.527"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428199909093730"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(98)04058-6"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.71.4.304"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2141.2001.02668.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2141.2001.02668.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2141.2001.02668.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T09:52:48Z","timestamp":1697536368000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2141.2001.02668.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,4]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2001,4]]}},"alternative-id":["10.1046\/j.1365-2141.2001.02668.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2141.2001.02668.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,4]]},"assertion":[{"value":"2002-01-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}